ATE210629T1 - Verbrückte zyklische aminosäuren als pharmazeutische mittel - Google Patents

Verbrückte zyklische aminosäuren als pharmazeutische mittel

Info

Publication number
ATE210629T1
ATE210629T1 AT97906630T AT97906630T ATE210629T1 AT E210629 T1 ATE210629 T1 AT E210629T1 AT 97906630 T AT97906630 T AT 97906630T AT 97906630 T AT97906630 T AT 97906630T AT E210629 T1 ATE210629 T1 AT E210629T1
Authority
AT
Austria
Prior art keywords
pct
amino acids
cyclic amino
pharmaceutical agents
bridged cyclic
Prior art date
Application number
AT97906630T
Other languages
English (en)
Inventor
David Christopher Horwell
Justin S Bryans
Clare O Kneen
Andrew I Morrell
Giles S Ratcliffe
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE210629T1 publication Critical patent/ATE210629T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/46—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing nine carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT97906630T 1996-03-14 1997-02-18 Verbrückte zyklische aminosäuren als pharmazeutische mittel ATE210629T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1343396P 1996-03-14 1996-03-14
PCT/US1997/002401 WO1997033859A1 (en) 1996-03-14 1997-02-18 Novel bridged cyclic amino acids as pharmaceutical agents

Publications (1)

Publication Number Publication Date
ATE210629T1 true ATE210629T1 (de) 2001-12-15

Family

ID=21759944

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97906630T ATE210629T1 (de) 1996-03-14 1997-02-18 Verbrückte zyklische aminosäuren als pharmazeutische mittel

Country Status (18)

Country Link
US (1) US6020370A (de)
EP (1) EP0888285B1 (de)
JP (1) JP2000506862A (de)
KR (1) KR100487032B1 (de)
AT (1) ATE210629T1 (de)
AU (1) AU731279B2 (de)
BR (1) BR9708180A (de)
CZ (1) CZ287598A3 (de)
DE (1) DE69709070T2 (de)
EA (1) EA001214B1 (de)
ES (1) ES2169848T3 (de)
IL (1) IL125364A0 (de)
NO (1) NO984204L (de)
NZ (1) NZ331142A (de)
PL (1) PL185990B1 (de)
SK (1) SK282848B6 (de)
WO (1) WO1997033859A1 (de)
ZA (1) ZA972199B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
KR100563894B1 (ko) 1997-09-18 2006-03-24 워너-램버트 캄파니 엘엘씨 가바펜틴 동족체의 신규 입체선택적 제조 방법
US6984659B2 (en) 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
DE19751062A1 (de) 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
US6518289B1 (en) * 1997-12-16 2003-02-11 Pfizer, Inc. 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
EP1082306A1 (de) * 1998-05-26 2001-03-14 Warner-Lambert Company Aminosäureverbindungen mit starrer konformation mit affinität für die alpha2delta untereinheit eines calciumkanals
DE69921137T2 (de) * 1998-07-09 2006-02-02 Warner-Lambert Co. Llc Pharmazeutische zusammensetzungen enthaltend gaba-analogen und ein antivirales mittel zur behandlung von herpes zoster
ES2287021T3 (es) 1999-07-22 2007-12-16 University Of Rochester Metodo para el tratamiento de sintomas de variacines hormonales que incluyen el fogaje.
JP2003528148A (ja) * 2000-03-28 2003-09-24 デロレンゾ、ロバート・ジェイ 損傷に際して神経細胞中に形成される新規カルシウム損傷電流の阻害は神経細胞死を抑制する
PL359872A1 (en) * 2000-06-26 2004-09-06 Warner-Lambert Company Gabapentin analogues for sleep disorders
AU2002230398A1 (en) 2000-10-06 2002-04-29 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
AU2002211863A1 (en) * 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
GB2374595A (en) * 2001-04-19 2002-10-23 Warner Lambert Co Fused bicyclic or tricyclic amino acids
BR0208922A (pt) * 2001-04-19 2004-04-20 Warner Lambert Co Aminoácidos bicìclicos ou tricìclicos fundidos
AU2002345638A1 (en) * 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CA2449729C (en) 2001-06-11 2009-11-03 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
AU2002316231A1 (en) * 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
AU2003222033A1 (en) 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
CA2484891A1 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7060727B2 (en) * 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
US20040162351A1 (en) * 2002-12-11 2004-08-19 Gallop Mark A. Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity
AU2003303041B2 (en) 2002-12-13 2008-07-24 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20050119676A (ko) * 2003-03-31 2005-12-21 제노포트 인코포레이티드 가바 유사체의 프로드러그를 사용한 열성 홍조의 치료 또는예방
KR20060119971A (ko) 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
AU2004271800A1 (en) 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
NZ579515A (en) 2003-09-17 2011-09-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
SG147437A1 (en) 2003-10-14 2008-11-28 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
MX2007005306A (es) * 2004-11-04 2007-06-11 Xenoport Inc Formas de dosis oral de liberacion sostenida de la prodroga gabapentina.
US8067402B2 (en) * 2005-12-12 2011-11-29 Allaccem, Inc. Methods and systems for coating an oral surface
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US20080161393A1 (en) * 2006-12-08 2008-07-03 Barrett Ronald W Use of prodrugs of GABA analogs for treating disease
CA2673545A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids
CA2683383C (en) 2007-02-21 2016-01-05 Allaccem, Incorporated Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
TW200908957A (en) * 2007-06-15 2009-03-01 Xenoport Inc Use of prodrugs of GABA analogs, antispasticity agents, and prodrugs of GABAB receptor agonists for treating spasticity
US8188068B2 (en) * 2007-08-10 2012-05-29 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in pets
US8153618B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for topical applications for pets
US8153617B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in humans
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US20090118365A1 (en) * 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
EP2250148B1 (de) 2008-01-25 2016-08-17 XenoPort, Inc. Kristalline form von kalziumsalzen von (3s)-aminomethyl-5-methylhexansäuren und anwendungsverfahren
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
ES2601852T3 (es) * 2008-01-25 2017-02-16 Xenoport, Inc. Forma cristalina de sales de calcio de ácidos (3S)-aminometil-5-metil-hexanoicos y métodos de uso
WO2010016584A1 (ja) * 2008-08-07 2010-02-11 杏林製薬株式会社 ビシクロ[２．２．２]オクチルアミン誘導体の製造方法
ES2589915T3 (es) 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
WO2010084798A1 (ja) * 2009-01-21 2010-07-29 第一三共株式会社 ３環性化合物
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
CA2903000C (en) 2013-01-28 2021-10-12 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of .beta.-alanine and use therefor
CA3099775A1 (en) 2018-05-14 2019-11-21 Xgene Pharmaceutical Inc. Process for making 1-(acyloxy)-alkyl-carabmate drug conjugates of naproxen and pregabalin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743742A (en) * 1969-06-17 1973-07-03 Merck & Co Inc Producing anti-fibrinolytic activity with aminobicycloacetic acid derivatives
US3641129A (en) * 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
YU36150B (en) * 1974-11-22 1982-02-25 Pliva Zagreb Process for preparing alpha-amino-1-adamantyl acetic acid
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2543821C2 (de) * 1974-12-21 1984-10-18 Gödecke AG, 1000 Berlin Bestimmte Salze und Ester von 1-Aminomethyl-1-cycloalkanessigsäuren und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids

Also Published As

Publication number Publication date
KR100487032B1 (ko) 2005-12-21
CZ287598A3 (cs) 1999-02-17
BR9708180A (pt) 1999-07-27
NO984204D0 (no) 1998-09-11
EA001214B1 (ru) 2000-12-25
PL185990B1 (pl) 2003-09-30
NZ331142A (en) 2001-04-27
KR19990087755A (ko) 1999-12-27
EP0888285B1 (de) 2001-12-12
DE69709070D1 (de) 2002-01-24
EA199800797A1 (ru) 1999-04-29
EP0888285A1 (de) 1999-01-07
SK282848B6 (sk) 2002-12-03
PL328800A1 (en) 1999-02-15
JP2000506862A (ja) 2000-06-06
NO984204L (no) 1998-09-11
US6020370A (en) 2000-02-01
WO1997033859A1 (en) 1997-09-18
IL125364A0 (en) 1999-03-12
DE69709070T2 (de) 2002-06-20
AU731279B2 (en) 2001-03-29
SK124898A3 (en) 1999-02-11
ES2169848T3 (es) 2002-07-16
ZA972199B (en) 1997-09-17
AU2127197A (en) 1997-10-01

Similar Documents

Publication Publication Date Title
ATE210629T1 (de) Verbrückte zyklische aminosäuren als pharmazeutische mittel
IS1990B (is) Nýstárlegar staðgengnar hringamínósýrur notaðar til lyfjagerðar
ATE218135T1 (de) Zyklischaminosäure als pharmazeutische mittel
DE69737719D1 (de) Substituierte gamma-aminobuttersäurederivate als arzneimittel
DE69921340D1 (de) Verzweigte alkylpyrrolidin-3-carbonsäuren
ATE228128T1 (de) Amino-heterocyclen zur verwendung als pharmazeutische mittel
CA2245647A1 (en) Novel bridged cyclic amino acids as pharmaceutical agents

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee